Nektar Therapeutics’s Collaboration agreement with Bristol-Myers Squibb

Ambrogio Visconti

Sidley advised Nektar Therapeutics (Nasdaq:NKTR) on a global strategic development and commercialization collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for Nektar’s CD122-biased agonist, NKTR-214. Bristol-Myers Squibb Company…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here